Travoprost versus latanoprost combinations in glaucoma:economic evaluation based on visual field deficit progression

References

• Friedman DS, Wolfs RC, O’Colmain BJ, Klein BE, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004;122:532–8
   Google Scholar
• American Academy of Ophthalmology. Preferred practice pattern. Primary open-angle glaucoma. Limited revision. San Francisco, CA: American Academy of Ophthalmology, 2003
   Google Scholar
• Tielsch JM, Sommer A, Katz J, Royall RM, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA 1991;266:369–74
   Google Scholar
• Ntim-Amponsah CT, Amoaku WM, Ofosu-Amaah S, Ewusi RK, et al. Prevalence of glaucoma in an African population. Eye 2004;18:491–7
   Google Scholar
• Leske MC, Connell AM, Wu SY, Nemesure B, et al. Incidence of open-angle glaucoma: the Barbados Eye Studies. The Barbados Eye Studies Group. Arch Ophthalmol 2001;119:89–95
   PubMed Web of Science ®Google Scholar
• Quigley HA, West SK, Rodriguez J, Munoz B, et al. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol 2001;119:1819–26
   PubMed Web of Science ®Google Scholar
• Varma R, Ying-Lai M, Francis BA, Nguyen BB, et al. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology 2004;111:1439–48
   PubMed Web of Science ®Google Scholar
• Klein BE, Klein R, Sponsel WE, Franke T, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology 1992;99:1499–504
   PubMed Web of Science ®Google Scholar
• Duggal P, Klein AP, Lee KE, Iyengar SK, et al. A genetic contribution to intraocular pressure: the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci 2005;46:555–60
   PubMed Web of Science ®Google Scholar
• Gordon MO, Beiser JA, Brandt JD, Heuer DK, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714–20; discussion 829–30
   Google Scholar
• Leske MC, Heijl A, Hussein M, Bengtsson B, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003;121:48–56
   PubMed Web of Science ®Google Scholar
• Nouri-Mahdavi K, Hoffman D, Coleman AL, Liu G, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 2004;111:1627–35
   Google Scholar
• Drance S, Anderson DR, Schulzer M. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol 2001;131:699–708
   Google Scholar
• Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998;126:498–505
   PubMed Web of Science ®Google Scholar
• Lichter PR, Musch DC, Gillespie BW, Guire KE, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943–53
   PubMed Web of Science ®Google Scholar
• AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429–40
   Google Scholar
• Halpern MT, Covert DW, Robin AL. Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects. Trans Am Ophthalmol Soc 2002;100:33–42
   Google Scholar
• Martinez de la Casa JM, Wieland H, Wells D, Sullivan K. Comparative efficacy and safety of fixed combinations of travoprost 0.004%/timolol 0.5% and latanoprost 0.005%/ timolol 0.5% in patients with open-angle glaucoma or ocular hypertension: a 1-year study. World Glaucoma Congress, Vienna, Austria, July 6–9, 2005
   Google Scholar
• Asrani S, Zeimer R, Wilensky J, Gieser D, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000;9:134–42
   PubMed Web of Science ®Google Scholar
• Bergea B, Bodin L, Svedbergh B. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology 1999;106:997–1004; discussion 1004–5
   Google Scholar
• Heijl A, Leske MC, Bengtsson B, Hyman L, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268–79
   PubMed Web of Science ®Google Scholar
• Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol 1991; 111:51–5
   Google Scholar
• Martinez-Bello C, Chauhan BC, Nicolela MT, McCormick TA, et al. Intraocular pressure and progression of glaucomatous visual field loss. Am J Ophthalmol 2000;129:302–8
   Google Scholar
• O’Brien C, Schwartz B, Takamoto T, Wu DC. Intraocular pressure and the rate of visual field loss in chronic open-angle glaucoma. Am J Ophthalmol 1991;111:491–500
   Google Scholar
• Odberg T. Visual field prognosis in advanced glaucoma. Acta Ophthalmol 1987;65:27–9
   Google Scholar
• Shirakashi M, Iwata K, Sawaguchi S, Abe H, et al. Intraocular pressure-dependent progression of visual field loss in advanced primary open-angle glaucoma: a 15-year follow-up. Ophthalmologica 1993;207:1–5
   PubMed Web of Science ®Google Scholar
• Spaeth GL. The effect of change in intraocular pressure on the natural history of glaucoma: lowering intraocular pressure in glaucoma can result in improvement of visual fields. Trans Ophthalmol Soc U K 1985;104:256–64
   PubMedGoogle Scholar
• Stewart WC, Chorak RP, Hunt HH, Sethuraman G. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol 1993;116:176–81
   PubMed Web of Science ®Google Scholar
• Vogel R, Crick RP, Newson RB, Shipley M, et al. Association between intraocular pressure and loss of visual field in chronic simple glaucoma. Br J Ophthalmol 1990;74:3–6
   PubMed Web of Science ®Google Scholar
• Zeimer RC, Wilensky JT, Gieser DK, Viana MA. Association between intraocular pressure peaks and progression of visual field loss. Ophthalmology 1991;98:64–9
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701–13; discussion 829–30
   Google Scholar
• Practice Management Information Corporation. Medical fees in the United States. Los Angeles, CA: Practice Management Information Corporation, 2004
   Google Scholar
• Morse AR, Yatzkan E, Berberich B, Arons RR. Acute care hospital utilization by patients with visual impairment. Arch Ophthalmol 1999;117:943–9
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics. 2003 National Health Interview Survey. US Government Printing Office, 2004
   Google Scholar
• Noecker RJ, Walt JG. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications. Am J Ophthalmol 2006;141(Suppl):S15–21
   Google Scholar
• Holmstrom S, Buchholz P, Walt J, Wickstrom J, et al. The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries. Curr Med Res Opin 2006;22:897–905
   PubMed Web of Science ®Google Scholar
• Goldberg LD, Walt J. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications. Pharmacoeconomics 2006;24:251–64
   PubMed Web of Science ®Google Scholar
• Vold SD, Riggs WL, Jackimiec J. Cost analysis of glaucoma medications: a 3-year review. J Glaucoma 2002;11: 354–8
   Google Scholar
• Stewart WC, Leech J, Sharpe ED, Kulze J, et al. An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension. Am J Manag Care 2002;8(Suppl):S240–8
   Google Scholar
• Kernick DP. Introduction to health economics for the medical practitioner. Postgrad Med J 2003;79:147–50
   PubMed Web of Science ®Google Scholar
• Kobelt G. Health economics, economic evaluation, and glaucoma. J Glaucoma 2002;11:531–9
   PubMed Web of Science ®Google Scholar
• Schmier JK, Halpern MT, Covert D. Patient-reported impact of age-related macular degeneration. International Society of Pharmacoeconomics and Outcomes Research 9th Annual International Meeting. May 16–19; Arlington, VA, 2004
   Google Scholar
• Gohdes DM, Balamurugan A, Larsen BA, Maylahn C. Age-related eye diseases: an emerging challenge for public health professionals. Prev Chronic Dis 2005;2:A17
   PubMedGoogle Scholar
• Jack CI, Smith T, Neoh C, Lye M, et al. Prevalence of low vision in elderly patients admitted to an acute geriatric unit in Liverpool: elderly people who fall are more likely to have low vision. Gerontology 1995;41:280–5
   PubMed Web of Science ®Google Scholar